Cancer stem cells, capable of self-renewal and multipotent differentiation, influence tumor behavior through a complex balance of symmetric and asymmetric cell divisions. Mechanisms regulating the dynamics of stem cells and their progeny in human cancer are poorly understood. In Drosophila, mutation of brain tumor (brat) leads to loss of normal asymmetric cell division by developing neural cells and results in a massively enlarged brain composed of neuroblasts with neoplastic properties. Brat promotes asymmetric cell division and directs neural differentiation at least partially through its suppression on Myc. We identified TRIM3 (11p15.5) as a human ortholog of Drosophila brat and demonstrate its regulation of asymmetric cell division and stem cell properties of glioblastoma (GBM), a highly malignant human brain tumor. TRIM3 gene expression is markedly reduced in human GBM samples, neurosphere cultures, and cell lines and its reconstitution impairs growth properties in vitro and in vivo. TRIM3 expression attenuates stem-like qualities of primary GBM cultures, including neurosphere formation and the expression of stem cell markers CD133, Nestin, and Nanog. In GBM stem cells, TRIM3 expression leads to a greater percentage dividing asymmetrically rather than symmetrically. As with Brat in Drosophila, TRIM3 suppresses c-Myc expression and activity in human glioma cell lines. We also demonstrate a strong regulation of Musashi-Notch signaling by TRIM3 in GBM neurospheres and neural stem cells that may better explain its effect on stem cell dynamics. We conclude that TRIM3 acts as a tumor suppressor in GBM by restoring asymmetric cell division. Cancer Res; 74(16); 4536-48. Ó2014 AACR.
Introduction
Glioblastoma (GBM) is the most malignant primary brain tumor in adults (1) . Glioma stem cells (GSC), or brain tumor-initiating cells, are a neoplastic subpopulation within GBMs that is highly tumorigenic and responsible for therapy resistance (2) (3) (4) . GSCs have characteristics similar to neural stem cells (NSC), with the capacity for self-renewing cell division and multipotent differentiation along neural and glial lines (2, (5) (6) (7) .
A shared trait and defining characteristic of stem cells is their ability to divide asymmetrically, giving rise to two nonidentical daughter cells, with one maintaining stemness and the other developing a differentiated state (8) . Intrinsic molecular pathways that direct asymmetric cell division and stem-like behavior in the developing Drosophila melanogaster nervous system have been partially elucidated and may provide insight into similar regulatory networks in GSCs (9) (10) (11) (12) . In Drosophila neural precursors, the asymmetric cellular localization of Numb, Prospero, and Brain tumor (Brat) during cell division determines daughter cell fate. Daughter cells that inherit them progress to terminal differentiation, whereas daughter cells without them retain stem cell function and the ability to divide asymmetrically. Mutations in cell fate determinants (numb, prospero, and brat) result in the inability of neural precursors to divide asymmetrically, leading to the accumulation of highly proliferative neuroblasts with pluripotent potential (11) (12) (13) (14) (15) . Brat and Prospero are sequestered into the daughter cell destined for differentiation, the ganglion mother cell, by the docking protein Miranda. Once segregated, Prospero acts as a transcriptional repressor that causes cell-cycle exit, whereas Brat acts as a translational repressor that guides the cellular differentiation program, terminating asymmetric division, and selfrenewal (12, 14, 16) .
Drosophila brat is characterized by a massively enlarged larval brain containing undifferentiated neuroblasts with neoplastic properties (10, 12, 13, 16) . Brat promotes differentiation at least partially through its translational repression of Myc (17, 18) . On the basis of its high degree of sequence homology and conserved functional domains, TRIM3 has been identified as a human ortholog of brat. Its potential significance to gliomagenesis has been inferred from its deletion in 25% to 30% of GBM samples (19) . Recent studies of GBM by the Cancer Genome Atlas (TCGA) indicate that deletions involving 11p15, in which TRIM3 resides, are highly specific to the proneural and G-CIMP subclasses of GBM (20) .
Tripartite motif (TRIM) proteins belong to the family of E3 ubiquitin ligases that have a TRIM containing RING finger domain, one or two zinc-binding B-box domains and coiledcoil domains ( Fig. 1A; ref. 21) . TRIM proteins are known to regulate critical cellular processes, including proliferation, apoptosis, and transcriptional regulation. Their dysfunction has been implicated in developmental disorders and a variety of cancers. For example, TRIM13 and TRIM19 have tumor-suppressive activity through a direct effect on the p53 regulatory protein, MDM2, whereas TRIM24 and TRIM28 suppress p53 stability and expression (21) . TRIM gene clusters are located on chromosomes 1, 4, 5, 6, 7, 11, and 17, and genes for more than 70 TRIM proteins have been identified, thus far (21) . TRIM3 was first identified and characterized as a brain-enriched RING finger protein with its gene localized to chromosome 11p15.5 (22) . In this study, we provide functional evidence that TRIM3 is a tumor suppressor in human GBM cell lines, patient-derived neurospheres and in in vivo xenografts. Mechanistically, TRIM3 reprograms GSCs toward asymmetric cell division and differentiation through it regulation of c-Myc and Musashi-Notch pathways.
Materials and Methods

Cell culture
The human GBM cell lines U87MG, LN229, LNZ308, and SF767, as well as their culture conditions, have been described previously (23, 24) . GBM neurosphere cultures were isolated from patient samples and established in culture as previously described and were used for experiments between passages 1 and 30 (25) . GBM neurospheres and normal human neural progenitor cells (NHNP; Lonza) were cultured in neurobasal-A media (Invitrogen) containing human epidermal growth factor (STEMCELL Technologies), basic fibroblast growth factor (STEMCELL Technologies), and GIBCO B-27 supplement and N2 supplement (Invitrogen). Both GBM neurosphere and NHNP cultures show consistent expression of the stem cell and CD133 þ ranged from 3% to 16%. Normal human astrocytes and human astrocytes sequentially transformed with hTERT, E6 and E7 have been previously described (26, 27) .
Real-time PCR Total RNA was extracted using TRizol reagent (Invitrogen) and converted to cDNA using a cDNA synthesis kit (Applied Biosystems). Real-time PCR assays were performed with the Power SYBR GREEN PCR master mix (Applied Biosystems) using a 7000 Sequence Detection System (Applied Biosystems). The sequences of human TRIM3, p21, cyclin D2, and GAPDH primers were designed as follows: TRIM3 forward: 5 0 -GGC-TGACTGGGGCAACAGCCGCATC-3 0 , reverse: 5 0 -ATCTGCA-GAACCACTGTATGGTCCA-3; p21 forward: 5 0 -ATTCAG-CATTGTGGGAGAG-3 0 and reverse: 5 0 -TGGACTGTTTTCTCT-CGGCT-3 0 ; Cyclin D2 forward: 5 0 -GCGGTGCTCCTCAATAG-3 0 and reverse: 5 0 -TGGCATCCTCACAGGTC-3 0 ; GAPDH forward: 5 0 -GAAGGTGAAGGTCGGAGTC-3 0 and reverse: 5 0 -GAAGATG-GTGATGG GATTTC-3 0 . PCR was run at 95 C for 10 minutes followed by 40 cycles at 95 C for 15 seconds and 60 C for 30 seconds. Transcript levels from GBM samples and cells were normalized to GAPDH and reported as relative fold increase compared with normal brain tissues or normal human astrocytes by the 2 ÀDDC t method as described previously (28) .
TRIM3 overexpression constructs
Transient expression constructs: pRNAT-Trim3 includes a 3.2-kb full-length Trim3 cDNA; pLenti6-Trim3 includes only the coding region (open reading frame) and a V5 tag; and pFUW-Trim3 includes the open reading frame, but no tag.
Lentivirus constructs
FUW-Trim3-GFP and FUW-Trim3 expression constructs were used. The Trim3-GFP fusion cDNA construct was derived from pCMV6-AC-Trim3-GFP TrueORF clone (RG211739; Origene). The vector was partially digested with FseI to avoid the cutting the other FseI site inside the GFP-coding region and with BamHI. The resulting 3-kb Trim3-GFP fusion cDNA fragment was ligated into the BamHI and FseI sites of the FUW vector, generating FUW-Trim3-GFP. The FUW-Trim3 construct was generated by amplifying the Trim3-coding region and cloning into the BamHI and HpaI sites of the FUW vector. The following primers were used: BamHI-TRIM3 5 0 -GGATCCGCCATGGCAAAGAGGGAGGACAGC-3 0 and HpaI-TRIM3 5 0 -GTTAACCTACTGGAGGTAGCGATAGGCTTT-3 0 . The FUW-GFP expression vector was previously described (23) .
TRIM3 short hairpin constructs
Three pairs of short hairpin oligos were designed against three different exon regions of the human TRIM3 gene (NM_006458). Two oligos of each pair were annealed and ligated into the pRNATin H1.4 vector (GeneScript), which was linearized with BamHI and XbaI (NEB). Lentiviral particle generation and infection Lentiviral vectors (3 mg) were prepared by cotransfecting them with packaging plasmids (6-mg pCMVDR8.72 and 1.5-mg pVSVG) in 2 Â 10 5 293FT cells using Lipofectamine 2000 (Invitrogen). After overnight incubation, medium was replaced and 48 or 72 hours later the conditioned medium containing viral particles was collected, cleared of cell debris by centrifugation at 100 Â g, and stored at À80 C. To establish stable cell lines, 5,000 cells each of U87MG or LN229 per well were seeded in 12-well plates. Of note, 1 mL of viral particles and 1 mL normal medium were added to each well and incubated for 48 hours. For GBM neurosphere, viral particles were collected and concentrated by ultracentrifugation at 25,000 rpm for 4 hours at 4
C. Viral pellets were resuspended in neurobasal-A media to prevent serum effects. Infection of cells and lentiviral-mediated gene expression were confirmed by demonstrating GFP expression by fluorescence microscopy and TRIM3 expression by Western blot analysis.
Cell proliferation assay
Stably infected cell lines U87MG-TRIM3, U87MG-GFP, LN229-TRIM3, and LN229-GFP cells were seeded in 96-well plates at a density of 2 Â 10 3 cells per well in 100 mL of DMEM media with 10% FBS. Cell proliferation was analyzed at 0, 24, 48, 72, 96, and 168 hours by sulforhodamine B assay (SigmaAldrich; ref. 29) .
Cell proliferation assay for neurospheres
Neurospheres from GBM samples and NHNP cells (Lonza) were measured with the MTT-based CellTiter96 Aqueous One Solution Cell Proliferation Assay Kit (Promega). Of note, 1,000 cells in 100 mL medium were seeded per well in 96-well plate. Of note, 20 mL MTS solution added into each well and incubated at 37 C for 2 hours. Absorbance was read at 490 nm using a Synergy HT microplate reader (BioTek).
Colony formation assay
A total of 1 Â 10 3 cells were resuspended in 0.5 mL 2Â DMEM with 20% FBS, mixed with 0.5 mL 0.7% ultrapure agarose (Invitrogen) in water and the mixture was layered on top of the 6-well plates containing 2 mL of solidified 0.5% base agarose in 20% FBS 2Â DMEM. Of note, 2 mL of the base agarose was loaded into each well of a 6-well plate and solidified the day before the experiment. After 5 weeks in culture, the colonies were stained with 0.5 mL 0.005% crystal violet (Sigma) in PBS and counted on a Gelcount Scanner (Oxford Optronix).
Flow cytometry
Analysis of stem cell markers in neurospheres was performed using antibodies against CD133 (Miltenyi Biotech) and Nestin (Abcam) analysis was done using BD FACSCanto II (BD Biosciences).
PKH26 assay
A total of 1 Â 10 6 GBM neurosphere cells were dissociated with Accutase (Innovative Cell Technology), followed by staining with the PKH26 Red fluorescent Cell Linker Mini Kit (Sigma-Aldrich). Briefly, dissociated cells were washed with 5-mL PBS at 400 Â g and resuspended in 0.5 mL diluent C. A total of 4 Â 10 À6 molar PKH26 dye was added to cells. After staining for 5 minutes, the reaction was stopped by adding 1-mL PBS with 1% BSA followed by 2-mL neurobasal-A media. Cells were mixed by inverting tubes several times and collected by centrifuging at 400 Â g. After washing three times with neurobasal-A media, stained neurosphere cells were cultured for 2 weeks for secondary neurosphere formation. Secondary neurospheres were then dissociated with Accutase and cells were sorted on a BD FACSAria II Cell Sorter (BD Biosciences). Sorted neurosphere cells were divided into three groups based on PKH26-staining intensity: PKH high , PKH low , and PKH negative cells. Fifty cells from each group were seeded onto each well of a 96-well plate and incubated under normal conditions. Symmetric and asymmetric cell divisions were monitored and photographed using a Zeiss Ax-10 fluorescence microscope (Zeiss).
Dual luciferase reporter assay A Cignal Reporter Assay Kit (SABiosciences) was used to measure c-Myc promoter-driven luciferase expression.
Western blot analysis
Western blot analysis was performed as previously described (23) . Antibodies used were against c-Myc (BD Pharmingen), TRIM3 (GeneTex), b-actin, serving as a loading control (Santa Cruz Biotechnology and GeneTex), p21 cip , p27 kip1 , cyclin D2, Notch, Numb, Hes1, and MS1 (Musashi; all Cell Signaling Technology). Goat-anti-mouse IgG or goat-anti-rabbit IgG conjugated to horseradish peroxidase (Bio-Rad) was used as secondary antibodies. Enhanced chemiluminescence was used for detection (Thermo Fisher Scientific).
Immunofluorescence analysis
Immunofluorescent staining was performed using antibodies against Nanog (1:100; BD Biosciences), Nestin 
DNA copy number and somatic mutation data
We downloaded copy number and somatic mutation data of GBM samples collected in the TCGA dataset from cBioPortal for Cancer Genomics (30). The Genomic Identification of Significant Targets in Cancer 2.0 was applied to DNA copy-number data to find driver genes targeted by somatic copy-number alterations accountable for cancer progression (31, 32) . We determined hemizygous and homozygous loss TRIM2, TRIM3, TRIM32, and TRIM71 for 497 patients. Somatic mutation and copy-number data were acquired for CDKN2A, EGFR, IDH1, NF1, PDGFRA, TP53, PTEN, and RB1 (33).
Gene-expression data
Normalized gene-expression data from the Agilent microarray platform were obtained through cBioPortal. We correlated in pairs the gene expression of TRIM2, TRIM3, TRIM32, and TRIM71 with that of MYC, NOTCH, NUMB, MSI, and NANOG with Pearson correlation, respectively. Correlation coefficients and P values were computed with gene-expression data of 547 patients.
Correlates of mRNA data with survival
Clinical information, including patient age, gender, treatment history, survival, and censoring status, was downloaded from the TCGA portal (34). Survival differences were investigated between groups of patients with the upper and lower quartile of TRIM3 expression. A Kaplan-Meier plot was produced and log-rank testing was carried out with survival data.
Transcriptional subtype class
TCGA GBMs are subdivided into four transcriptional subtypes based on unsupervised hierarchical clustering [Proneural (PN), Neural (NR), Classical (CL) and Mesenchymal (MS); ref. 35] . Subtypes for samples absent from this dataset were determined with Prediction Analysis of Microarray software version 2.21 using RMA normalized Affymetrix HT-HGU133 mRNA expression platform data. A sample expression average was computed for samples with multiple corresponding arrays. Unlogged expression was filtered to remove probes with a fold change less than 1.5 or an expression range less than 20.
Integration of TRIM3 deletion with transcriptional class and genetic alterations
To investigate the relationship of TRIM3 deletion with geneexpression subtypes, we used the hypergeometric distribution to calculate the significance of TRIM3 deletion as either enriched or depleted in a specific transcriptional subtype. We computed the P value of the significance test as the sum of the probabilities of all cases as equal as or more extreme than the observed data. A test with the P value of <0.05 was considered significant. Similar tests were conducted to study the relationship between TRIM3 deletion and GBM genetic alterations, including DNA copy-number alterations and mutations of genes CDKN2A, EGFR, IDH1, MDM2, NF1, NOTCH1, NOTCH2, PDGFRA, PTEN, P53, and RB1.
Animal studies
All animal experiments were performed under approved protocols of the institutional animal use and care committee. For intracranial tumor inoculation, 1 Â 10 5 cells were stereotactically implanted into the right striatum of 4-to 6-week-old female athymic nude mice (12 mice/group; Foxn1nu; Harlan). Animal survivals were compared using the Kaplan-Meier survival analysis and log-rank testing.
Statistical analysis
Quantitative data are expressed as mean AE SE. ANOVA was used to compare group differences. Statistical significance was assessed by the Student t test. Differences were considered to be significant when P < 0.05. Survival analysis was performed using Kaplan-Meier curves and significance was determined using the log-rank test.
Results
TRIM3 deletion and reduced expression in human gliomas
Potential human orthologs of Drosophila brat, based on sequence homology, include TRIM2 (36), TRIM3 (19, 22) , TRIM32 (37), and TRIM71 (38), located on chromosomes 4q31.3, 11p15.5, 9q33.1, and 3p22.3, respectively. We focused our investigations on TRIM3 as the human ortholog because: (i) TRIM3 has the highest homology to Drosophila brat ( Fig.  1A ; ref. 10); (ii) TRIM3 is specifically expressed in human brain, much like the expression of brat is specific to Drosophila neural tissue; and (iii) SNP-based analysis of TRIM3 revealed loss in 25% of GBMs (19) and our own probing of the TCGA data indicated that TRIM3 has the highest frequency of deletion among TRIM family members. TRIM3 was deleted in 22% of GBMs, whereas TRIM2, TRIM32, and TRIM71 were deleted in 12%, 11%, and 10% of cases, respectively ( Fig. 1B; ref. 30) .
Further in silico analysis of TRIM3 in human gliomas was performed using the independent REMBRANDT dataset, which includes all histologies and grades of gliomas, including astrocytomas and oligodendrogliomas of grades 2, 3, and 4 (39). TRIM3 (11p15.5) deletions were noted in 24% of all glioma samples (Fig. 1C ) and were seen in both astrocytic and oligodendroglial histologies, grades 2, 3, and 4. Deletions were as frequent in the lower-grade neoplasms as GBM, grade 4, suggesting that TRIM3 loss is an early neoplastic step.
Interestingly, we found that those GBMs with TRIM3 deletion were highly enriched in the proneural transcriptional class, as defined by the TCGA (P ¼ 1.23eÀ07), and depleted in the classical transcriptional class (P ¼ 8.71eÀ11; refs. 30, 35). In addition, TRIM3 deletion was found to be highly enriched in IDH1-mutant (P ¼ 0.00031), PDGFRA-amplified (P ¼ 0.00061), and TP53-mutant (P ¼ 0.00013) GBMs, all of which are characteristic of the proneural transcriptional class. The association of IDH1 mutation with TRIM3 deletion may partially explain the higher percentage of TRIM3 deletions in grade 2 astocytomas than grade 3 astrocytomas, because the latter have a lower frequency of IDH mutations (40) . TRIM3 deletion was depleted in EGFR-amplified (P ¼ 8.4459eÀ8), CDKN2A-deleted (P ¼ 1.71128eÀ5), and PTEN-deleted (P ¼ 0.0056) GBMs, which are all typical of the classical expression class. The strong association of TRIM3 deletion with the proneural transcriptional class suggests that its loss is associated with gene expression related to neural developmental and proliferation, because these categories are enriched in this expression class (35) .
TRIM3 gene expression was substantially lower in GBMs and lower-grade gliomas (astrocytomas, oligodendrogliomas of grades 2 and 3) as compared with normal brain (data not shown; ref. 41). In TCGA data, we found that TRIM3 deletion in GBM (22%) was associated with reduced gene expression as compared with nondeleted GBMs (P ¼ 0.000097). Because TRIM3 expression was also noted to be low in GBMs without TRIM3 deletion, we explored other mechanisms that might explain low gene expression. We compared DNA methylation levels of TRIM3 with that of glial fibrillary acidic protein (GFAP) and found that TRIM3 was methylated to a greater degree than GFAP (n ¼ 112; P ¼ 0.0041), suggesting that the DNA methylation might explain reduced expression (30). Although TRIM3 deletion was not associated with a shorter survival among GBMs, we found that those GBMs with the highest gene expression (top quartile) had a longer survival than those with lowest gene expression, yet this did not reach statistical significance (P ¼ 0.28; Fig. 2A; ref. 30 ). This slightly shorter survival associated with low TRIM3 expression may be due to the association of TRIM3 loss with the proneural transcriptional class, which has the shortest survival among GBM classes once the IDH-mutant tumors have been removed from this group (20) . Although TRIM3 loss was also associated with IDH1 mutations, which have prolonged survivals, there were very few IDH1 mutants in our study TCGA set (n ¼ 8 IDH1 mutants; n ¼ 85 proneural GBMs).
To verify in silico findings, we analyzed TRIM3 transcript levels in human GBM tissue samples and cell lines with quantitative real-time PCR and found that TRIM3 mRNA expression was substantially lower in GBMs than normal human brain (Fig. 2B) . Similarly, normal human astrocytes in culture showed higher basal expression of TRIM3 transcript than GBM cell lines or human astrocytes that were sequentially transformed with hTERT, E6, and E7 oncoproteins (Fig. 2C) . TRIM3 protein expression could be consistently identified as an 80-kDa band in normal brain (lanes 1-3) but was markedly reduced in human GBM samples (lanes 4-9; Fig. 2D ). The samples shown in Fig. 2D do not correspond to those samples in Fig. 2B . As compared with control tissues, TRIM3 protein levels were reduced in GBM samples to a greater extent than mRNA levels (Fig. 2B) . Furthermore, TRIM3 was not detectable by Western blot analysis in any of the GBM cell lines (data not shown).
TRIM3 expression suppresses glioma proliferation and colony formation
To better understand the functional consequences of TRIM3 loss in glioma progression, we focused on lentiviral-mediated restoration of TRIM3 protein expression in GBM cell lines and neurospheres. Restoration of TRIM3 protein in GBM cell lines (Fig. 3A) and neurospheres (Fig.  3B) led to a significant reduction in their in vitro growth over the course of 8 days, with the first signs noted around day 4. TRIM3-overexpressing GBM cells also showed a marked reduction in anchorage-independent colony formation in soft agar over the course of 30 days, with only 12% of the colonies formed as compared with GFP-expressing controls (Fig. 3C) . The differing band patterns for the actin loading controls on Western blots in Fig. 3 , resulted from the use of two different antibodies. Combined, the results suggest that TRIM3 restoration in GBM cells reduces their in vitro growth.
Conversely, to investigate effects of reducing TRIM3 expression in normal brain cells, we used lentiviral-mediated knockdown in NHNP cells (Fig. 3D) . NHNPs with TRIM3 shRNA knockdown showed a significant increase in cell growth as compared with controls by day 3, indicating that TRIM3 regulates the expansion of neural cells that are not transformed.
We next examined the effect of TRIM3 expression on glioma growth in vivo. We intracranially injected 10 5 control or TRIM3-expressing glioma cells into the parietal region of nude mice. Mice that received intracranial injections of U87 or U87-GFP control cells had 50% survivals at 33 and 38 days, respectively. Mice injected with U87-TRIM3 had significantly longer 50% survival at 53 days (log-rank test, P < 0.05; Fig. 3E ). Thus, TRIM3 expression in GBM cell lines suppressed tumor growth both in vitro and in vivo.
TRIM3 promotes differentiation and suppresses stem cell markers in GBM neurosphere cultures
We next investigated the role of TRIM3 in regulating GSC properties using neurosphere cultures. We used flow cytometry to measure the expression of Nestin and CD133 in dispersed GBM neurosphere cells stably transfected with GFP or TRIM3-GFP constructs. The percentage of Nestinexpressing cells was significantly higher in neurosphere cells expressing GFP (16%) than in those expressing TRIM3-GFP (3.5%; Fig. 4A ). The percentage of CD133 þ cells was only modestly greater in neurosphere cells expressing GFP (0.71%) than those expressing TRIM3-GFP (0.63%). The percentage of neurosphere cells expressing both Nestin and CD133 in the GFP-expressing cells, although small (0.46%), was slightly greater than that of expressing GFP-TRIM3 (0.26%).
To further investigate the effects of TRIM3 on stemness, we used immunofluorescence microscopy of whole GBM neurospheres and dispersed cells in culture under basal conditions (no serum; Fig. 4B ). We found that TRIM3 expression was consistently associated with reduced expression of the stem cell marker Nanog under basal conditions (Fig. 4B) . Thus, our data indicate that TRIM3 expression may be capable of reprogramming GBM neurosphere cells from a stem cell phenotype toward a more differentiated phenotype. 
TRIM3 reduces the PKH-26-high population in GBM neurosphere cultures
To interrogate the role of TRIM3 specifically in regulating cell division within the GSC compartment, we used PKH-26, a fluorescent membrane dye that is partitioned evenly to daughter cells at the time of cell division and is maintained in highest concentration by cells that divide slowly. Previous studies have shown that PKH-26-high cells demonstrate asymmetric cell division; have the greatest degree of stemness; and have the highest tumorigenic potential (42) . N08-74-GFP and N08-74-TRIM3 neurospheres were stained with PKH-26, allowed to divide for 14 days, and then subjected to flow cytometry. We found that there was a population shift with regard to PKH-26 expression, with N08-74-TRIM3 cells showing lower PKH-26 expression than N08-74-GFP. However, the percentage of PKH-26-high cells in N08-74-TRIM3 cells was lower (0.47%) than N08-74-GFP cells (1.27%), suggesting that TRIM3 attenuates this GSC population (Fig. 4C) . Combined with the flow cytometry data on Nestin and CD133, our findings strongly suggest that the GSC population is substantially reduced in TRIM3-expressing neurospheres.
TRIM3 reduces sphere formation and favors asymmetric cell division in GBM stem cells
We next investigated TRIM3 for its effect on the ability of primary GBM cultures to form neurospheres, a GSC-dependent function. Cultures established from GBM samples in neural basal media (lacking serum) follow a fairly consistent sequence, with dispersed single cells forming neurospheres ranging from 0.1 to 1 mm over the course of 96 hours. We found that N08-74-TRIM3 cultures consistently formed fewer and smaller neurospheres than controls (N08-74 or N08-74-GFP cultures; Fig. 5A ). Thus, TRIM3 impairs the ability of GBM explants to form neurospheres.
We next evaluated the impact of TRIM3 expression on cell division, specifically within a PKH-26-high (GSC) population. After 14 days following PKH-26 staining, we isolated individual PKH-26-high cells from both the N08-74-GFP and N08-74-TRIM3-GFP cultures and replated them at low density (10 cells/well in 96-well plates). We observed and quantified cell division patterns in these two cell types. In N08-74-GFP PKHhigh cells (Fig. 5B, top) , we found a consistent pattern of 1-2-4-8 cells (symmetric cell division, 76.2%; asymmetric cell division, 23.8%). Neurosphere cells that expressed TRIM3 (Fig. 5B,  bottom) showed multiple patterns of cell division, including 1-2-3-5, 1-2-3-6, and 1-2-3-4 (asymmetric cell division, 82.9%; symmetric cell division, 17.1%). Thus, within the PKH-high cell population, TRIM3 expression leads to a switch from predominantly symmetric cell division to asymmetric cell division.
TRIM3 represses c-Myc expression and activity in human gliomas and astrocytes
Drosophila Brat protein promotes asymmetric cell division and neural differentiation at least partially through repression of c-Myc (12) . On the basis of this, we investigated the relationship between TRIM3 and c-Myc in human gliomas. In the TCGA GBM data, we observed that c-Myc was overexpressed and TRIM3 was underexpressed in nearly all GBM samples (Fig. 6A) . We also noted a statistically significant negative correlation between TRIM3 expression and c-Myc in the same samples (P < 0.05, r ¼ À0.235, Fig. 6B ). To formally test the causative nature of this relationship, we stably transfected LN229 GBM cells with either GFP-or TRIM3-GFP-expressing lentiviral constructs and showed that TRIM3 was exclusive to the cytoplasm of TRIM3-GFP-expressing cells, whereas no observable TRIM3 protein was detected in GFP control cells (Fig. 6C ). As compared with control GFP-expressing cells, nuclear c-Myc expression was significantly reduced in TRIM3-GFP cells (Fig. 6C) . We further investigated the effects of TRIM3 on the expression of positively (cyclin D2) and negatively (p21 and p27) regulated c-Myc target genes. With overexpression of TRIM3, cyclin D2 levels were decreased, whereas p27 and p21 levels were markedly increased (Fig. 6D) . We also examined effects of downregulating TRIM3 expression on p21 mRNA levels in normal human astrocytes, which have a high basal expression of TRIM3. Normal astrocytes were stably infected with TRIM3-shRNA constructs, resulting in significant knockdown of TRIM3, as well as a reduction in the level of p21 transcript levels (Fig. 6E) . To confirm the suppressive effect of TRIM3 on c-Myc, we used a c-Myc-driven luciferase reporter in U87MG and LN229 GBM cell lines infected with GFP-or A SSC-A
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Neurosphere-GFP TRIM3-GFP-expressing lentiviruses. In both cell lines, TRIM3 overexpression led to a significant reduction in luciferase activity (Fig. 6F) . Collectively, these data confirm the suppressive effect of TRIM3 on c-Myc levels and transcriptional activity in cultured glioma cell lines.
TRIM3 regulates the Musashi-Notch pathway in neural and GBM neurospheres
To better understand mechanisms of the TRIM3-mediated control of differentiation and cell division, we investigated the impact of TRIM3 on c-Myc expression and its target genes in NHNP cells and GBM neurosphere cultures, because these preparations contain a stem cell component. We established stable NHNP neurosphere lines using TRIM3-knockdown (shTrim3) or GFP-expressing (GFP) lentiviruses (Fig. 7A) . NHNPs with TRIM3-shRNA showed significantly reduced TRIM3 protein and, as with glioma cell lines, showed increased levels of c-Myc expression compared with GFP controls. Contrary to expectations and findings in established glioma cell lines (U87MG and LN229), expression of the c-Myc target p21 was not inhibited by increased c-Myc expression and the expression of cyclin D2 was not altered. We further probed these cultures for signaling pathways regulated by TRIM3 that might explain the discrepancy between c-Myc expression and its target genes. Because the Notch pathway is known to regulate p21, we started by investigating the Musashi/Notch pathway. Musashi is an RNA-binding protein that activates the Notch signaling by inhibiting Numb translation and preventing degradation of Notch-1 (43, 44) . Numb normally binds to the Notch-1 intracellular domain (NICD) and reduces the expression of downstream targets such as Hes-1. In NHNP control neurospheres (NHNP-GFP), we found that high basal TRIM3 expression correlated with low Musashi expression, high Numb expression and low Notch activity, as determined by Hes-1 expression. Inhibition of TRIM3 in these neurospheres (NHNP-sh-TRIM3) led to significant upregulation of Musashi, downregulation of Numb, and increased expression of the Notch-1 target Hes-1 (Fig. 7B) . Consistent with these findings in NHNP, restoration of TRIM3 in GBM neurospheres led to reduced levels of Musashi and Hes-1 (Fig. 7C, left) . Immunofluorescence studies corroborated the inverse relationship between TRIM3 and Musashi expression (Fig. 7C, right) . Thus, data from NHNP and GBM neurospheres strongly suggest a role of TRIM3 in regulating the Musashi-Numb-Notch signaling axis.
Discussion
The regulation of asymmetric stem cell division is complex and poorly understood in mammalian systems. Because the undifferentiated neuroblasts that accumulate in Drosophila brat have neoplastic properties, disruption of similar regulatory mechanisms in human brain tumors may affect stem cell dynamics and favor neoplastic growth (15) . Among human genes, we and others have found that TRIM3 has the highest homology with brat (10, 19) .
TRIM3 loss (11p15.5) is detected in approximately 25% of GBMs, as well as in lower-grade gliomas. Although gene expression of TRIM3 was lowest in those GBMs with deletion, it was also reduced in nearly all GBMs based on analysis of the TCGA data. Mechanisms responsible for low TRIM3 expression in nondeleted gliomas are not known. However, it is possible that DNA methylation may be at least partially responsible. The 11p15 region is a site of frequent dysregulated DNA methylation and loss of imprinting, with disrupted methylation in this region implicated in numerous developmental and neoplastic diseases (45, 46) . Our own analysis of TCGA GBMs indicated that TRIM3 showed significantly increased methylation levels compared with GFAP, which may partially explain its reduced expression in nondeleted gliomas. Interestingly, we found that TRIM3 deletion was highly associated with the proneural transcriptional class of GBM, which is enriched for genes that regulate neural developmental and proliferation (35) . This tight association indicates that TRIM3 loss is a marker for a specific transcriptional form of malignant glioma, potentially one with more neural stem-like qualities. In our own investigations of GBM patient samples, neurosphere cultures and established glioma cell lines, TRIM3 mRNA and protein expression were low or absent in all samples. Our studies of the functional consequence of TRIM3 overexpression and knockdown in GBM cell lines and neurospheres indicated that TRIM3 has tumor-suppressive activity, decreases cellular proliferation in vitro, and slows tumor growth in vivo. Because Drosophila Brat is a repressor of protooncogene c-Myc, we examined this relation in human gliomas and observed that TRIM3 indeed suppresses c-Myc expression and activation/repression of its target genes in established GBM cell lines (12, 15) . Others have also described the regulation of p21 by TRIM3 in glioma cell lines (47) .
Because we were interested in furthering our investigations in cellular models that contain a stem cell population and mimic the human disease to a greater extent, we investigated neurosphere cultures derived from human GBM explants as well as their nonneoplastic counterpart, NHNP, which also grow as 3D neurospheres. In these preparations, we also observed that TRIM3 was capable of suppressing c-Myc; however, downstream targets of c-Myc, such as p21 and cyclin D2, did not correlate with c-Myc levels and suggested that other key regulatory networks that control proliferation and differentiation may also be under the control of TRIM3.
We observed that TRIM3 expression was strongly associated with suppressed expression of the stem cell markers Nestin, Nanog, and Musashi, consistent with our hypothesis that it may antagonize stem-like behavior. Musashi is an RNA-binding protein that promotes stem cell self-renewal by activating Notch signaling. Musashi binds the 3 0 untranslated region of Numb mRNA and inhibits its translation. Numb normally binds to intracellular domain of Notch (NICD) to inhibit signaling. Thus, Musashi activates Notch signaling by removing the repression on NICD (48) . Musashi has been shown to promote growth and survival of glioma cells by activating Notch and PI3K signaling (44) . Our results indicate that in NHNP and GBM neurospheres, TRIM3 regulates proliferation and differentiation through the Musashi/Numb/Notch pathway, in addition to c-Myc.
We observed that TRIM3 expression by glioma channels the cell population away from an undifferentiated, stem-like state. By flow cytometry, immunofluorescence, and Western blots, TRIM3 restoration in GBM neurospheres was associated with reduced expression of stem cell markers, such as Nestin, Musashi, and Nanog. We also observed that TRIM3 expression within a stem cell population (PKH-high) leads to a greater proportion undergoing asymmetric cell division and reduces the ability of aggregated GBM cells to form neurospheres. Taken together, we conclude that loss of TRIM3 during gliomagenesis increases the GSC population by disrupting asymmetric cell division and cellular differentiation.
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